Health Condition 1: K580- Irritable bowel syndrome with diarrhea
Conditions
Interventions
Intervention1: Bacillus subtilis HU58 Plus Bacillus coagulans SC208 Capsules: One capsule twice daily for 28 days
Control Intervention1: Placebo Capsules: One capsule twice daily for 28 day
Sponsors
Synergia Life Sciences Pvt Ltd A Novozymes One Health Company
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male or Female subjects between 18 to 65 years of age both inclusive. 2. Subjects diagnosed with diarrhoea-predominant irritable bowel syndrome (IBS-D) as per ROME IV criteria: i. Recurrent abdominal pain on average at least one day/week in the last three months, associated with two or more of the following criteria: - Related to defecation - Associated with a change in stool frequency (increase/decrease in frequency). - Associated with a change in the form (appearance) of stool. ii. History of abnormal bowel movements predominantly diarrhoea ( >25% of bowel movement categorized as stool form type 6 or 7 (diarrhoea) and 3. Subjects who are willing to sign informed consent for participation in the study and willing to adhere to all protocol procedures. 4. At end of screening period - Abdominal Pain Intensity: weekly average of worst daily (in past 24 hours) abdominal pain score of = 3.0 on a 0 to 10-point scale and - At least one stool with a consistency of Type 6 or Type 7 Bristol stool score (BSS) on at least 2 days per week).
Exclusion criteria
Exclusion criteria: 1. Subjects with Constipation-predominant irritable bowel syndrome (IBS), or diarrhoea other than that associated with IBS. 2. Subjects with known hypersensitivity to any of the ingredients in the probiotic product or the placebo. 3. Subjects with a history of coeliac disease, Inflammatory Bowel disease, bowel cancer, bariatric surgery or surgical resection of the stomach, small intestine, or large intestine. 4. Subjects with history of unexplained weight loss or rectal bleeding. 5. Subjects with acute GI tract infection 6. Subjects requiring antibiotics for the treatment of Diarrhoea 7. Subjects with Type 1 Diabetes or Uncontrolled Type 2 Diabetes Mellitus. 8. Subjects with clinically significant illnesses of cardiovascular, endocrine, immune, respiratory, hepato-biliary, kidney and urinary, haematological, musculoskeletal system and/or any inflammatory disorder, and other gastrointestinal diseases. 9. Use of antidepressant agents, unless used at a stable dose for at least 2weeks prior to screening. 10. Subjects with current evidence of clinically significant severe, unstable, or uncontrolled cardiovascular, pulmonary, hepatic, renal, hematopoietic, Neurologic, psychiatric, autoimmune disease and other relevant systemic diseases that would preclude the safe administration of the Investigational product. 11. Subjects with history of HIV or hepatitis B or hepatitis C at screening visit. 12. Subjects with a history of food allergies and lactose intolerance. 13. Subject with history of alcohol or drug abuse in the past 3 months prior to screening visit. 14. Subjects with a history of intake of Any Probiotic, Prebiotic, symbiotic containing formulations, antibiotics (Rifaximin, metronidazole, or any other), Bile acid sequestrants(Cholestyramine ,Colesevelam and Colestipol), 5-hydroxytryptamine (serotonin) 3 receptor antagonists (such as Alosetron) and Eluxadoline within two weeks prior to the screening day. 15. Female subjects who are pregnant or lactating or planning to become pregnant during the study period. Females who are not ready to use acceptable contraceptive methods during the course of study. 16. Concurrent participation in another clinical trial or any investigational therapy within 30 days prior to signing informed consent. 17. Suspected inability or unwillingness to comply with the study procedures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of subjects defined as responders for abdominal pain and stool consistency from baseline to end of study.Timepoint: 28 Days | — |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of subjects who were responders for abdominal pain from baseline to the end of study.Timepoint: 28 Days;Percentage of subjects who were responders for Stool Consistency Scores from baseline to the end of study.Timepoint: 28 Days;Change in Stool Consistency (Bristol stool score (BSS) from baseline to the end of studyTimepoint: 28 Days;Change in Abdominal Pain Intensity (0 to 10 point NRS scale) from baseline to the end of study.Timepoint: 28 Days;Change in Perceived Stress Scale (PSS) from baseline to the end of study.Timepoint: 28 Days;Percentage of IBS Global Assessment of Improvement Scale (IBS-GAI) responders from baseline to the end of study.Timepoint: 28 Days;Change in stool sample measurement for Short-chain fatty acids SCFAs levels from baseline to the end of studyTimepoint: 28 Days;Changes in diversity of gut microbiota observed through DNA extraction and 16S rRNA gene sequencing from baseline to the end of studyTimepoint: 28 Days | — |
Countries
India
Contacts
Public ContactDr Shashank S Jadhav
Biosphere Clinical Research Pvt.Ltd
Outcome results
None listed